DNLI SCHEDULE 13G/A: SEC filing
T. Rowe Price Investment Management, Inc.
Filed with the SEC on · accession 0001897612-26-000739
DNLI filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. A report the company filed with the SEC (the US market regulator). The stock moved -1.9% by the first close after the filing.
Summary of the filing
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting beneficial ownership of 19,634,011 shares, or 12.3%, of Denali Therapeutics Inc. common stock as of September 30, 2026.
Key details
How DNLI stock reacted
Close before
$18.74
Nov 13, 2026
First close after
-1.89%
$18.39
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for DNLI, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for DNLI?
Click hereFrequently asked questions
What did DNLI file with the SEC on Nov 16, 2026?
DNLI filed a SCHEDULE 13G/A (SEC filing). T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting beneficial ownership of 19,634,011 shares, or 12.3%, of Denali Therapeutics Inc. common stock as of September 30, 2026.
How do I read a SCHEDULE 13G/A?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).
How did DNLI stock react to this filing?
DNLI closed at $18.74 before the filing and $18.39 on Nov 16, 2026 (-1.89%).
Other DNLI SEC filings
Get alerts when DNLI files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days